Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.02.2015 | main topic

Cathepsin K-Inhibitoren: präklinische und klinische Daten

verfasst von: Dr. Marion Gamsjäger, MD, Prim. Univ. Prof. Dr. Heinrich Resch

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Cathepsin K ist eine Cysteinproteinase und somit ein essentielles Enzym in der Degradation von Kollagen Typ I. Es wird fast ausschließlich in Osteoklasten exprimiert. Aufgrund des physiologischen Mechanismus stellt diese Protease einen pharmakologischen Angriffspunkt für die Entwicklung neuer Medikamente in der Osteologie dar. In den letzten Jahrzehnten wurde intensiv daran geforscht, hochwirksame, selektive und oral einnehmbare Cathepsin K-Inhibitoren zu entwickeln. Im Gegensatz zu Balicatib und Relacatib, deren Weiterentwicklung wegen kutaner Nebenwirkungen bei relativ geringer Spezifität eingestellt wurde, wendete sich die Forschung den spezifischeren Cathepsin K-Inhibitoren Odanacatib (ODN) und ONO-5334 zu. So hebt Odanacatib bei postmenopausalen Frauen sehr deutlich die Knochenmineraldichte und hemmt die Knochenresorption. Als Voraussetzung für die Weiterentwicklung konnte in einer Langzeituntersuchung die Sicherheit und Wirksamkeit des Medikaments bestätigt werden. Jedoch nehmen nach dessen Absetzen Knochenresorption und Knochenmasseverlust wieder zu. Eine Phase III Frakturpräventionsstudie an postmenopausalen Frauen mit Osteoporose befindet sich derzeit in der Endphase.
Vorheriger Artikel Treatment of osteoporosis: current state of the art
Nächster Artikel Reduction of coronary risk factors immediately and 1 year after inpatient rehabilitation in a highly motivated patient cohort
Literatur
1.
Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18(5):585–600.CrossRefPubMedCentralPubMed
2.
Bromme D, Okamoto K, Wang BB, et al. Human cathepsin O2, a matrix protein-degrading cysteineprotease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem. 1996 Jan 26;271(4):2126–32.CrossRefPubMed
3.
Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996;271(21):12517–24.CrossRefPubMed
4.
Kafienah W, Bromme D, Buttle DJ, et al. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triplehelix. Biochem J. 1998;331(3):727–32.PubMedCentralPubMed
5.
Garnero P, Borel O, Byrjalsen I, Ferreras M, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998;273(48):32347–52.CrossRefPubMed
6.
Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc (Tokyo). 2003;52(6):551–8.CrossRef
7.
Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236–8.CrossRefPubMed
8.
Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 1998;95(23):13453–8.CrossRefPubMedCentralPubMed
9.
Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14(10):1654–63.CrossRefPubMed
10.
Rood JA, Van Horn S, Drake FH, et al. Genomic organization and chromosome localization of the human cathepsin K gene (CTSK). Genomics. 1997;41(2):169–76.CrossRefPubMed
11.
Lecaille F, Bromme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie. 2008;90(2):208–26.CrossRefPubMed
12.
Xia L, Kilb J, Wex H, et al. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem. 1999;380(6):679–87.CrossRefPubMed
13.
Sassi ML, Eriksen H, Risteli L, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone. 2000;26(4):367–73.CrossRefPubMed
14.
Mano H, Yuasa T, Kameda T, et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun. 1996;223(3):637–42.CrossRefPubMed
15.
Furuyama N, Fujisawa Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids. 2000;65(7):371–8.CrossRefPubMed
16.
Parikka V, Lehenkari P, Sassi ML, et al. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology. 2001;142(12):5371–8.CrossRefPubMed
17.
Fujisaki K, Tanabe N, Suzuki N, et al. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci. 2007;80(14):1311–8.CrossRefPubMed
18.
Zhao Q, Jia Y, Xiao Y. Cathepsin K: a therapeutic target for bone diseases. Biochem Biophys Res Commun. 2009;380(4):721–3.CrossRefPubMed
19.
Falgueyret JP, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005;48(24):7535–43.CrossRefPubMed
20.
Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008;73(1):147–56.CrossRefPubMed
21.
Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008;59(1):125–9.CrossRefPubMed
22.
Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007;40(1):122–31.CrossRefPubMed
23.
Perez-Castrillon JL, Pinacho F, De Luis D, et al. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J Osteoporos. 2010 : 401581. doi:10.4061/2010/401581.
24.
Gauthier JY, Chauret N, Cromlish W, Desmarais S, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18(3):923–8.CrossRefPubMed
25.
Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7:447–56. doi:10.1038/nrrheum.2011.77.CrossRefPubMed
26.
27.
Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009;86(2):175–82.CrossRefPubMed
28.
Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–47.PubMed
29.
Nagase S, Ohyama M, Hashimoto Y, et al. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K Inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. Br J Clin Pharmacol. 2012;74(6):959–70.CrossRefPubMedCentralPubMed
30.
Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242–51.CrossRefPubMed
31.
Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of boneloss after discontinuation of treatmentof postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875–83.CrossRefPubMed
32.
Sornay-Rendu E, Garnero P, Munoz F, et al. Effect of withdrawal of hormone replacement therapy on bonemass and bone turnover: the OFELY study. Bone. 2003;33(1):159–66.CrossRefPubMed
33.
Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.CrossRefPubMed
34.
Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.CrossRefPubMed
35.
Bauer DC. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow? J Bone Miner Res. 2011;26(2):239–41. doi:10.1002/jbmr.335.CrossRefPubMed
36.
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.CrossRefPubMed
37.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.CrossRefPubMed
38.
Anderson M, Gendrano I, Liu C, Jeffers S, et al. Odanacatib in older men. J Clin Endocrinol Metab. 2014;99(2):552–60.CrossRefPubMed
39.
Bonnick S, Villiers T, Odio A, et al. Odanacatib in women previously treated with alendronate. J Clin Endocrinol Metab. 2013;98(12):4727–35.CrossRefPubMed
40.
Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251–8. doi:10.1177/1759720×13490860.CrossRefPubMed
41.
Cusick T, Chen CM, Pennypacker BL, et al., Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27(3):524–37.CrossRefPubMed
42.
Jayakar RY, Cabal A, Szumiloski J, et al. Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone. 2012;50(6):1379–88. doi:10.1016/j.bone.2012.03.017CrossRefPubMed
43.
Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27(3):509–23. doi:10.1016/j.bone.2013.06.008CrossRefPubMed
44.
Cheung AM, Majumdar S, Brixen KR, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture and estimated bone strength. J Bone Miner Res. 2014;29:1786–94. doi:10.1002/jbmr.2194CrossRefPubMed
45.
Engelke K, Fürst T, Dardzinski B, et al. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women – results of a 2-year placebo-controlled trial. J Bone Miner Res. 2014 June 4. doi: 10.1002/jbmr.2292
Metadaten
Titel
Cathepsin K-Inhibitoren: präklinische und klinische Daten
verfasst von
Dr. Marion Gamsjäger, MD
Prim. Univ. Prof. Dr. Heinrich Resch
Publikationsdatum
01.02.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0336-3

Weitere Artikel der Ausgabe 3-4/2015

Treatment of osteoporosis: current state of the art

  • main topic

Reduction of coronary risk factors immediately and 1 year after inpatient rehabilitation in a highly motivated patient cohort

  • original article

Myiasis on squamous cell carcinoma of skin

  • brief report

Molecular and cellular basis of bone resorption

  • main topic

Cathepsin K inhibitors: emerging treatment options for osteoporosis

  • editorial